Bis-furan derivatives as transthyretin (TTR) stabilizers and amyloid inhibitors for the treatment of familial amyloid polyneuropathy (FAP)
The design and synthesis of a novel bis-furan scaffold tailored for high efficiency at inhibiting transthyretin amyloid formation is reported. In vitro results show that the discovered compounds are more efficient inhibitors of amyloid formation than tafamidis, a drug currently used in the treatment of familial amyloid polyneuropathy (FAP), despite their lower molecular weight and lipophilicity. Moreover, ex vivo experiments with the strongest inhibitor in the series, conducted in human blood plasma from normal and FAP Val30Met-transthyretin carriers, disclose remarkable affinity and selectivity profiles. The promises and challenges facing further development of this compound are discussed under the light of increasing evidence implicating transthyretin stability as a key factor not only in transthyretin amyloidoses and several associated co-morbidities, but also in Alzheimer's disease.
1. A compound of Formula (I):
or pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or prodrug thereof, wherein:
—Y is —CH═CH— or —CH 2 —CH 2 —;
R 1 is H or —CH 3 ;
R 2 is —OR a , —C(═O)OR a , —S(═O) 2 NHR a , —S(═O) 2 OR a , —P(═O)NH 2 (OR a ), —C(═O)N(R a ) 2 , —C(═O)NHOR a , or —CHN 4 (tetrazolyl);
R 3 is H or —CH 3 ;
R 4 is H, —OH, Halogen, —CH 3 , or —OCH 3 ;
R 5 is H, F, —CN, —SH, —OR a , —S(═O) 2 NHR a , —S(═O) 2 OR a , —P(═O)NH 2 (OR a ), —C(═O)NHOR a , or —CHN 4 (tetrazolyl);
R 6 is H, —OH, Halogen, —CH 3 , or —OCH 3 ; and
each instance of R a is independently H, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, or an oxygen protecting group when attached to an oxygen atom, or two instances of R a are joined to form a substituted or unsubstituted, heterocyclic ring, or substituted or unsubstituted, heteroaryl ring.
2. The compound according to claim 1 , wherein the compound is of the formula:
or pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or prodrug thereof.
3. The compound of claim 1 , or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or prodrug thereof, wherein —Y— is —CH═CH—.
4. The compound according to claim 3 , or pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or prodrug thereof, wherein the C═C double bond connecting the two furan rings is of (E)-configuration.
5. The compound according to claim 3 , or pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or prodrug thereof, wherein the C═C double bond connecting the two furan rings is of (Z)-configuration.
6. The compound of claim 1 , or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or prodrug thereof, wherein R 2 is —C(═O)OR a .
7. The compound of claim 1 , or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or prodrug thereof, wherein R 4 is H.
8. The compound of claim 1 , or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or prodrug thereof, wherein R 5 is H.
9. The compound of claim 1 , or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or prodrug thereof, wherein R 6 is halogen.
10. The compound of claim 1 , or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or prodrug thereof, wherein —Y— is —CH 2 —CH 2 —.
11. The compound of claim 1 , or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or prodrug thereof, wherein each instance of R a is H.
12. The compound of claim 1 , or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof.
13. A pharmaceutical preparation comprising the compound according to claim 1 , or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or prodrug thereof, and a pharmaceutically acceptable carrier.
14. A method of inhibiting amyloid fibril formation in a subject, the method comprising administering to said subject an effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or prodrug thereof.
15. A method of ameliorating an amyloid disease, the method comprising administering to a subject in need thereof an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or prodrug thereof.
16. The method according to claim 15 , wherein the amyloid disease is AA amyloidosis, Alzheimer's Disease, Light-Chain (AL) amyloidosis, Type-2 Diabetes, Medullary Carcinoma of the Thyroid, Parkinson's disease, Polyneuropathy, or Spongiform Encephalopathy.
17. The method according to claim 15 , wherein the amyloid disease is Creutzfeldt Jakob disease.
18. The method according to claim 15 , the method comprising administering to a subject in need thereof an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof.
19. The method according to claim 15 , wherein the amyloid disease is familial amyloid polyneuropathy.
20. The method according to claim 15 , wherein the amyloid disease is familial amyloid cardiomyopathy.
21. The method according to claim 15 , wherein the amyloid disease is senile systemic amyloidosis.